Hospital
Spectrum Health Hospitals
Spectrum Health Hospitals was paid $243.22M by Medicaid between Jan 2018 and Dec 2024, across 1025 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoSPECTRUM HEALTH HOSPITALS
GRAND RAPIDS, MI 49503
GRAND RAPIDS, MI 49503
33aNPI1922090554assigned 08/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$243.22M
24GClaims7,025,479
24DCodes billed1025
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#2 of 86
Median peer was paid$21.55M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COX, MATTHEW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 685,049 | $21.70M | |
| 2019 | 598,917 | $18.94M | |
| 2020 | 807,895 | $26.90M | |
| 2021 | 1,290,559 | $44.65M | |
| 2022 | 1,253,601 | $44.55M | |
| 2023 | 1,255,962 | $44.82M | |
| 2024incomplete | 1,133,496 | $41.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 145,643 | 131,689 | $30.11M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 73,523 | 66,977 | $27.29M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.1% | 154,792 | 143,786 | $19.81M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.0% | 242,360 | 201,656 | $14.68M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 3.5% | 3,216 | 3,202 | $8.44M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 83,122 | 73,708 | $7.72M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 90,133 | 84,488 | $5.40M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 142,946 | 53,244 | $3.93M |
| G0378 | Hospital observation service, per hour | 1.6% | 37,600 | 21,923 | $3.89M |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 1.5% | 3,364 | 2,782 | $3.60M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 24,823 | 24,046 | $3.35M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 10,057 | 10,008 | $3.08M |
1013 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 12,198 | $2.90M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.1% | 26,567 | $2.63M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 33,148 | $2.42M |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 4,238 | $2.14M |
| 47562 | <1% | 748 | $2.09M | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 7,555 | $1.97M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 57,515 | $1.83M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 9,538 | $1.82M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 3,952 | $1.77M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 4,048 | $1.72M |
| 44970 | <1% | 596 | $1.72M | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 43,695 | $1.70M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 10,175 | $1.66M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 3,862 | $1.65M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 16,946 | $1.52M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 3,183 | $1.47M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14,597 | $1.46M |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,907 | $1.46M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 1,222 | $1.44M |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 66,924 | $1.44M |
| 93975 | <1% | 10,306 | $1.20M | |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 1,420 | $1.18M |
| 95782 | <1% | 2,298 | $1.16M | |
| 82947 | <1% | 61,191 | $1.13M | |
| 36415 | Collection of venous blood by venipuncture | <1% | 375,552 | $1.12M |
| 43249 | <1% | 1,512 | $1.12M | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 64,391 | $1.12M |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 18,366 | $1.09M |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 375 | $1.05M |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,510 | $1.05M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 72,853 | $1.00M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 71,841 | $978K |
| 59025 | Fetal non-stress test | <1% | 10,422 | $953K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 6,224 | $940K |
| J2350 | Injection, ocrelizumab, 1 mg | <1% | 64 | $906K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 58,009 | $876K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 15,053 | $855K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 7,879 | $844K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 21,430 | $830K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 11,412 | $787K |
| 92526 | <1% | 17,168 | $749K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,287 | $743K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 23,256 | $721K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 17,233 | $717K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 10,311 | $706K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 40,884 | $695K |
| 49452 | <1% | 1,589 | $645K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 23,802 | $643K |
| 58661 | <1% | 234 | $630K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 2,601 | $627K |
| 86900 | <1% | 25,719 | $617K | |
| 95715 | <1% | 3,194 | $612K | |
| 80050 | General health panel | <1% | 22,056 | $610K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,833 | $593K |
| 76830 | Ultrasound, transvaginal | <1% | 10,413 | $586K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 19,724 | $579K |
| 76770 | <1% | 9,880 | $573K | |
| 97162 | <1% | 12,398 | $572K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 22,637 | $566K |
| 80061 | Lipid panel | <1% | 60,021 | $560K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 7,795 | $534K |
| 95816 | <1% | 3,602 | $528K | |
| 52356 | <1% | 217 | $521K | |
| 80053 | Comprehensive metabolic panel | <1% | 244,201 | $510K |
| 77386 | <1% | 1,868 | $509K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 10,327 | $504K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,098 | $498K |
| C9399 | Unclassified drugs or biologicals | <1% | 7,748 | $497K |
| 36430 | <1% | 2,904 | $492K | |
| 71045 | Radiologic examination, chest; single view | <1% | 14,036 | $489K |
| 97161 | <1% | 9,942 | $483K | |
| 72141 | <1% | 3,476 | $471K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 9,915 | $450K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 3,633 | $442K |
| J2357 | Injection, omalizumab, 5 mg | <1% | 460 | $436K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 6,165 | $422K |
| 42830 | <1% | 283 | $413K | |
| 92587 | <1% | 2,845 | $413K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 49,055 | $409K |
| 43235 | <1% | 1,205 | $406K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,115 | $401K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 24,511 | $399K |
| 72197 | <1% | 1,469 | $393K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 61,306 | $391K |
| 76801 | <1% | 6,631 | $383K | |
| 19083 | <1% | 484 | $381K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 45,045 | $379K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 1,129 | $361K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 4,703 | $350K |
| 75561 | <1% | 1,359 | $335K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 777 | $323K |
| 81229 | <1% | 637 | $321K | |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 1,032 | $320K |
| 20680 | <1% | 366 | $312K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 7,516 | $309K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 319 | $303K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 935 | $302K |
| 74183 | <1% | 2,158 | $302K | |
| 70498 | <1% | 2,529 | $295K | |
| 96415 | <1% | 6,443 | $294K | |
| 58558 | <1% | 227 | $293K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 51 | $293K |
| 49650 | <1% | 92 | $287K | |
| 96409 | <1% | 2,512 | $287K | |
| 95700 | <1% | 3,224 | $280K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 217,813 | $279K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 10,346 | $276K |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 25,078 | $274K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 25,608 | $255K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 391 | $251K |
| 77334 | <1% | 787 | $250K | |
| 0002A | <1% | 7,419 | $248K | |
| 58571 | <1% | 51 | $247K | |
| 76642 | <1% | 6,335 | $242K | |
| 92523 | <1% | 2,489 | $235K | |
| 70491 | <1% | 2,179 | $232K | |
| 93971 | <1% | 4,629 | $231K | |
| 25605 | <1% | 304 | $230K | |
| 87506 | <1% | 2,452 | $222K | |
| 10060 | <1% | 2,418 | $219K | |
| 86780 | <1% | 28,135 | $214K | |
| 90671 | <1% | 988 | $213K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,463 | $207K |
| 76536 | <1% | 4,510 | $207K | |
| 93458 | <1% | 130 | $201K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 253 | $200K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13,028 | $199K |
| 72158 | <1% | 2,013 | $197K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,884 | $196K |
| 54161 | <1% | 294 | $193K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 12,836 | $192K |
| 0001A | <1% | 7,816 | $190K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 11,847 | $189K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 17,594 | $185K |
| 77066 | Tomosynthesis, mammo | <1% | 3,383 | $184K |
| 36561 | <1% | 150 | $182K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 8,025 | $181K |
| 72156 | <1% | 1,426 | $181K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,652 | $181K |
| 97165 | <1% | 4,064 | $181K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 4,629 | $179K |
| 95811 | <1% | 482 | $178K | |
| 73221 | <1% | 1,512 | $177K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 72,552 | $173K |
| 49083 | <1% | 488 | $173K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 50,704 | $171K |
| 86480 | <1% | 6,350 | $170K | |
| 73222 | <1% | 436 | $168K | |
| 82728 | <1% | 29,403 | $162K | |
| 96367 | <1% | 4,331 | $162K | |
| 93970 | <1% | 1,704 | $160K | |
| 71250 | <1% | 3,005 | $159K | |
| 94060 | <1% | 1,051 | $159K | |
| 85027 | <1% | 91,836 | $157K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,912 | $154K |
| 97597 | <1% | 1,989 | $154K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,236 | $153K |
| 86003 | <1% | 4,797 | $151K | |
| 77336 | <1% | 2,445 | $151K | |
| 92611 | <1% | 3,175 | $146K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 3,842 | $141K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,811 | $140K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 34,214 | $140K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 235 | $137K |
| 97166 | <1% | 3,107 | $136K | |
| 64400 | <1% | 973 | $133K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 135 | $132K |
| 52332 | <1% | 108 | $125K | |
| 77065 | Tomosynthesis, mammo | <1% | 3,079 | $125K |
| 95819 | <1% | 836 | $123K | |
| 86870 | <1% | 935 | $123K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,796 | $122K |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 525 | $121K |
| 19318 | <1% | 39 | $120K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 473 | $119K |
| 84702 | <1% | 25,179 | $117K | |
| 70543 | <1% | 339 | $117K | |
| 80074 | <1% | 5,404 | $114K | |
| 93308 | <1% | 1,196 | $114K | |
| 92610 | <1% | 3,028 | $114K | |
| 72100 | <1% | 4,929 | $111K | |
| 96450 | <1% | 688 | $110K | |
| 87653 | <1% | 8,418 | $109K | |
| 97163 | <1% | 2,566 | $109K | |
| 76882 | <1% | 2,974 | $108K | |
| 64615 | <1% | 770 | $105K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 49,070 | $104K |
| 64450 | <1% | 1,266 | $101K | |
| 90686 | <1% | 15,968 | $101K | |
| 96376 | <1% | 24,379 | $100K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 7,776 | $99K |
| 87077 | <1% | 32,544 | $98K | |
| 74018 | <1% | 7,301 | $97K | |
| 70486 | <1% | 3,093 | $96K | |
| 97116 | <1% | 7,489 | $95K | |
| 83970 | <1% | 5,733 | $94K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,473 | $92K |
| 90651 | <1% | 2,714 | $91K | |
| 78264 | <1% | 455 | $90K | |
| 77300 | <1% | 463 | $89K | |
| 88184 | <1% | 1,916 | $89K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 7,507 | $89K |
| 83550 | <1% | 24,120 | $88K | |
| 90750 | <1% | 599 | $87K | |
| 84439 | <1% | 22,202 | $87K | |
| 72146 | <1% | 1,419 | $87K | |
| 83655 | <1% | 13,711 | $86K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 4,663 | $86K |
| 87563 | <1% | 5,210 | $86K | |
| 10005 | <1% | 295 | $84K | |
| 67311 | <1% | 85 | $84K | |
| 84403 | <1% | 6,501 | $83K | |
| 87081 | <1% | 33,296 | $82K | |
| 74178 | <1% | 584 | $79K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,841 | $78K |
| 93017 | <1% | 2,926 | $78K | |
| 82607 | <1% | 13,393 | $77K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 91,228 | $77K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 6,767 | $75K |
| 73610 | <1% | 9,412 | $74K | |
| 87186 | <1% | 23,721 | $72K | |
| 97802 | <1% | 1,977 | $69K | |
| 91322 | <1% | 666 | $69K | |
| 88342 | <1% | 5,123 | $69K | |
| 97760 | <1% | 2,133 | $68K | |
| 83540 | <1% | 24,508 | $67K | |
| 58662 | <1% | 26 | $66K | |
| 73562 | <1% | 7,507 | $66K | |
| 76886 | <1% | 1,574 | $66K | |
| 87529 | <1% | 3,052 | $66K | |
| 27447 | <1% | 12 | $66K | |
| 74240 | <1% | 848 | $65K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13,481 | $64K |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 1,370 | $63K |
| 82670 | <1% | 4,544 | $63K | |
| 74230 | <1% | 701 | $63K | |
| 64721 | <1% | 91 | $62K | |
| 90739 | <1% | 747 | $62K | |
| 93351 | <1% | 275 | $61K | |
| 73630 | <1% | 8,348 | $61K | |
| 87205 | <1% | 48,869 | $60K | |
| 77072 | <1% | 1,278 | $60K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 5,206 | $57K |
| 93798 | <1% | 914 | $55K | |
| 73030 | <1% | 5,709 | $55K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 1,346 | $54K |
| 74174 | <1% | 415 | $54K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 5,426 | $53K |
| 93225 | <1% | 1,833 | $53K | |
| 73130 | <1% | 6,701 | $53K | |
| 82784 | <1% | 11,616 | $51K | |
| 72157 | <1% | 735 | $50K | |
| 71271 | <1% | 1,051 | $50K | |
| 87070 | <1% | 17,525 | $50K | |
| 31575 | <1% | 639 | $48K | |
| 95076 | <1% | 245 | $48K | |
| 97763 | <1% | 1,456 | $48K | |
| 31624 | <1% | 131 | $47K | |
| 92652 | <1% | 349 | $46K | |
| 87340 | <1% | 20,810 | $46K | |
| 74220 | <1% | 616 | $46K | |
| 76881 | <1% | 705 | $46K | |
| 95712 | <1% | 680 | $45K | |
| 88307 | <1% | 4,168 | $45K | |
| 84402 | <1% | 3,515 | $45K | |
| 73110 | <1% | 5,190 | $44K | |
| 73140 | <1% | 3,645 | $44K | |
| 85610 | <1% | 35,506 | $44K | |
| 83880 | <1% | 11,501 | $44K | |
| 86235 | <1% | 1,517 | $43K | |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 220 | $43K |
| 86140 | <1% | 28,828 | $43K | |
| 86008 | <1% | 976 | $43K | |
| 83735 | <1% | 45,689 | $43K | |
| 90480 | <1% | 1,135 | $43K | |
| 82746 | <1% | 6,714 | $43K | |
| 81001 | <1% | 132,368 | $42K | |
| 83001 | <1% | 4,762 | $41K | |
| 82570 | <1% | 23,900 | $41K | |
| 84146 | <1% | 4,392 | $41K | |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | <1% | 93 | $40K |
| 77412 | <1% | 324 | $40K | |
| 76870 | <1% | 2,591 | $40K | |
| 73700 | <1% | 833 | $40K | |
| 70496 | <1% | 2,621 | $39K | |
| 80076 | <1% | 11,011 | $39K | |
| 86923 | <1% | 3,035 | $39K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 334 | $38K |
| 86038 | <1% | 6,756 | $38K | |
| 72040 | <1% | 2,024 | $38K | |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | <1% | 683 | $38K |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 441 | $37K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 50 | $36K |
| 83516 | <1% | 6,949 | $36K | |
| 96161 | <1% | 2,408 | $36K | |
| 92585 | <1% | 320 | $34K | |
| 42821 | <1% | 25 | $34K | |
| 84425 | <1% | 3,519 | $34K | |
| 58670 | <1% | 12 | $33K | |
| 74455 | <1% | 317 | $33K | |
| 58301 | <1% | 255 | $33K | |
| 99381 | <1% | 481 | $32K | |
| 85055 | <1% | 5,454 | $32K | |
| 36224 | <1% | 15 | $32K | |
| 87808 | <1% | 18,992 | $31K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 10,136 | $31K |
| 76080 | <1% | 178 | $30K | |
| 78227 | <1% | 106 | $29K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,674 | $29K |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 222 | $29K |
| G0422 | Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session | <1% | 503 | $29K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 469 | $29K |
| 73502 | <1% | 2,998 | $28K | |
| 92586 | <1% | 404 | $28K | |
| 90732 | <1% | 302 | $28K | |
| 93246 | <1% | 2,161 | $27K | |
| 54640 | <1% | 15 | $27K | |
| 87799 | <1% | 2,868 | $26K | |
| 86160 | <1% | 3,258 | $26K | |
| 82950 | <1% | 9,649 | $26K | |
| 72082 | <1% | 806 | $25K | |
| 77338 | <1% | 156 | $25K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 372 | $25K |
| 97803 | <1% | 1,163 | $25K | |
| 93296 | <1% | 1,648 | $25K | |
| 80197 | <1% | 5,017 | $24K | |
| 93304 | <1% | 126 | $24K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 92 | $24K |
| 64415 | <1% | 1,108 | $24K | |
| 95909 | <1% | 160 | $24K | |
| 93750 | <1% | 478 | $23K | |
| 87147 | <1% | 11,603 | $23K | |
| 82533 | <1% | 3,087 | $23K | |
| 86769 | <1% | 1,064 | $23K | |
| 84481 | <1% | 2,666 | $23K | |
| 73080 | <1% | 3,516 | $23K | |
| 94621 | <1% | 164 | $23K | |
| 90670 | <1% | 6,176 | $22K | |
| 80069 | <1% | 8,097 | $22K | |
| 64642 | <1% | 64 | $22K | |
| 87497 | <1% | 2,802 | $22K | |
| 84478 | <1% | 1,379 | $22K | |
| 83002 | <1% | 2,598 | $22K | |
| 97035 | <1% | 4,196 | $22K | |
| 85652 | <1% | 26,634 | $22K | |
| 49591 | <1% | 14 | $22K | |
| 82043 | <1% | 8,741 | $22K | |
| 43247 | <1% | 55 | $22K | |
| 88304 | <1% | 5,414 | $21K | |
| 0071A | <1% | 578 | $21K | |
| 93242 | <1% | 2,570 | $21K | |
| 83013 | <1% | 588 | $20K | |
| 86376 | <1% | 2,782 | $20K | |
| 96116 | <1% | 135 | $20K | |
| 82105 | <1% | 3,053 | $20K | |
| 78816 | <1% | 26 | $20K | |
| 85007 | <1% | 28,779 | $19K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,577 | $19K |
| 73564 | <1% | 1,244 | $19K | |
| 92522 | <1% | 331 | $19K | |
| 95910 | <1% | 131 | $19K | |
| 72070 | <1% | 573 | $18K | |
| 86665 | <1% | 2,674 | $18K | |
| 73590 | <1% | 4,215 | $18K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 44 | $18K |
| 84100 | <1% | 19,348 | $18K | |
| 96127 | <1% | 4,803 | $18K | |
| 38222 | <1% | 12 | $17K | |
| 72131 | <1% | 539 | $17K | |
| 82785 | <1% | 2,490 | $17K | |
| 90746 | <1% | 268 | $17K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 63 | $17K |
| 96411 | <1% | 442 | $17K | |
| 86706 | <1% | 3,810 | $17K | |
| 84305 | <1% | 2,085 | $16K | |
| 58300 | <1% | 986 | $16K | |
| 86200 | <1% | 2,582 | $16K | |
| 84156 | <1% | 15,137 | $15K | |
| 91010 | <1% | 66 | $15K | |
| 86225 | <1% | 2,758 | $15K | |
| 97022 | <1% | 2,549 | $15K | |
| 75574 | <1% | 227 | $15K | |
| 83993 | <1% | 1,573 | $15K | |
| 95908 | <1% | 101 | $15K | |
| 0054A | <1% | 495 | $15K | |
| 0072A | <1% | 403 | $15K | |
| 82951 | <1% | 2,043 | $15K | |
| 95951 | <1% | 113 | $15K | |
| 85240 | <1% | 2,217 | $15K | |
| 72110 | <1% | 402 | $15K | |
| 86696 | <1% | 1,554 | $15K | |
| 86364 | <1% | 2,935 | $14K | |
| 85246 | <1% | 1,904 | $14K | |
| 84144 | <1% | 1,338 | $14K | |
| 77080 | <1% | 241 | $14K | |
| 70487 | <1% | 182 | $14K | |
| 95117 | <1% | 656 | $13K | |
| 82977 | <1% | 4,353 | $13K | |
| 77301 | <1% | 24 | $13K | |
| 88112 | <1% | 1,666 | $13K | |
| 84590 | <1% | 2,396 | $13K | |
| 92557 | <1% | 246 | $13K | |
| 72072 | <1% | 902 | $13K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,979 | $13K |
| 83690 | <1% | 43,673 | $13K | |
| 84630 | <1% | 2,525 | $13K | |
| 98968 | <1% | 750 | $12K | |
| 87517 | <1% | 617 | $12K | |
| 92579 | <1% | 923 | $12K | |
| 94010 | <1% | 1,201 | $12K | |
| 87328 | <1% | 1,934 | $12K | |
| 78999 | <1% | 96 | $12K | |
| 0012A | <1% | 371 | $12K | |
| 78830 | <1% | 18 | $12K | |
| 73660 | <1% | 861 | $12K | |
| 43242 | <1% | 14 | $12K | |
| 82565 | <1% | 35,386 | $12K | |
| 82627 | <1% | 1,112 | $12K | |
| 73090 | <1% | 3,495 | $11K | |
| 84703 | <1% | 74,130 | $11K | |
| 84153 | <1% | 1,389 | $11K | |
| 90656 | <1% | 1,454 | $11K | |
| 76000 | <1% | 2,657 | $11K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 302 | $11K |
| 85097 | <1% | 99 | $11K | |
| 43762 | <1% | 85 | $11K | |
| 85730 | <1% | 11,491 | $11K | |
| 0124A | <1% | 300 | $11K | |
| 92604 | <1% | 156 | $11K | |
| 25600 | <1% | 98 | $11K | |
| 90621 | <1% | 390 | $10K | |
| C1769 | Guide wire | <1% | 9,058 | $10K |
| 86255 | <1% | 1,623 | $10K | |
| 87329 | <1% | 1,920 | $10K | |
| 82247 | <1% | 4,810 | $10K | |
| 82550 | <1% | 5,872 | $10K | |
| 86695 | <1% | 1,554 | $10K | |
| 73552 | <1% | 2,323 | $10K | |
| 83615 | <1% | 9,295 | $10K | |
| 82248 | <1% | 5,295 | $10K | |
| 81025 | <1% | 11,446 | $10K | |
| 74019 | <1% | 2,019 | $10K | |
| 86431 | <1% | 3,652 | $10K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,839 | $10K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 80,499 | $10K |
| 86147 | <1% | 461 | $10K | |
| 86905 | <1% | 172 | $10K | |
| 80164 | <1% | 2,050 | $10K | |
| 0004A | <1% | 272 | $9K | |
| 90734 | <1% | 1,875 | $9K | |
| 73521 | <1% | 549 | $9K | |
| 84446 | <1% | 1,443 | $9K | |
| 0011A | <1% | 391 | $9K | |
| 0052A | <1% | 246 | $9K | |
| 0031A | <1% | 254 | $9K | |
| 29105 | <1% | 113 | $9K | |
| 90678 | <1% | 29 | $9K | |
| 85245 | <1% | 1,116 | $9K | |
| 96417 | <1% | 215 | $8K | |
| 20610 | <1% | 90 | $8K | |
| 84550 | <1% | 5,129 | $8K | |
| 85046 | <1% | 7,973 | $8K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 738 | $8K |
| 86704 | <1% | 1,660 | $8K | |
| 97130 | <1% | 288 | $8K | |
| 86341 | <1% | 402 | $8K | |
| 69610 | <1% | 12 | $8K | |
| 73060 | <1% | 1,466 | $8K | |
| 91320 | <1% | 92 | $8K | |
| 43237 | <1% | 13 | $8K | |
| 71101 | <1% | 598 | $8K | |
| 0051A | <1% | 202 | $7K | |
| 86146 | <1% | 345 | $7K | |
| 99495 | <1% | 121 | $7K | |
| 82274 | <1% | 890 | $7K | |
| 78320 | <1% | 40 | $7K | |
| 83021 | <1% | 2,731 | $7K | |
| 85018 | <1% | 7,782 | $7K | |
| 82525 | <1% | 1,271 | $7K | |
| 84484 | <1% | 37,345 | $7K | |
| 76010 | <1% | 525 | $7K | |
| 76604 | <1% | 242 | $7K | |
| 73200 | <1% | 157 | $7K | |
| 87184 | <1% | 2,046 | $7K | |
| 85397 | <1% | 700 | $7K | |
| 72170 | <1% | 1,118 | $7K | |
| 36590 | <1% | 12 | $7K | |
| 40899 | <1% | 72 | $7K | |
| 99385 | <1% | 97 | $6K | |
| 70544 | <1% | 117 | $6K | |
| 64405 | <1% | 46 | $6K | |
| 73000 | <1% | 1,274 | $6K | |
| 78306 | <1% | 38 | $6K | |
| 73722 | <1% | 14 | $6K | |
| 74160 | <1% | 54 | $6K | |
| 84165 | <1% | 1,266 | $6K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 501 | $6K |
| C1753 | Catheter, intravascular ultrasound | <1% | 403 | $6K |
| 36416 | <1% | 17,523 | $6K | |
| 93880 | <1% | 65 | $6K | |
| Q0114 | Fern test | <1% | 1,107 | $6K |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 1,866 | $6K |
| 86803 | <1% | 1,075 | $6K | |
| 64447 | <1% | 522 | $6K | |
| 91200 | <1% | 91 | $5K | |
| 86762 | <1% | 10,184 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 36 | $5K |
| 84681 | <1% | 593 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 58,680 | $5K |
| 84460 | <1% | 2,106 | $5K | |
| 87206 | <1% | 4,712 | $5K | |
| 82140 | <1% | 1,765 | $5K | |
| 86304 | <1% | 663 | $5K | |
| 87109 | <1% | 569 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 276 | $5K |
| 31622 | <1% | 12 | $5K | |
| C8924 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study | <1% | 37 | $5K |
| 86787 | <1% | 2,663 | $5K | |
| 86360 | <1% | 280 | $5K | |
| 87338 | <1% | 606 | $5K | |
| 74270 | <1% | 51 | $4K | |
| 87102 | <1% | 3,159 | $4K | |
| 86618 | <1% | 641 | $4K | |
| 29515 | <1% | 52 | $4K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 56 | $4K |
| 83921 | <1% | 455 | $4K | |
| 87536 | <1% | 115 | $4K | |
| 87324 | <1% | 788 | $4K | |
| 51798 | <1% | 1,612 | $4K | |
| G0515 | Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes | <1% | 136 | $4K |
| 84450 | <1% | 1,767 | $4K | |
| 85300 | <1% | 696 | $4K | |
| 90473 | <1% | 564 | $4K | |
| 82330 | <1% | 8,614 | $4K | |
| 86359 | <1% | 281 | $4K | |
| 88173 | <1% | 1,560 | $4K | |
| 82390 | <1% | 832 | $4K | |
| 16020 | <1% | 155 | $4K | |
| 87040 | <1% | 11,062 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 50,202 | $4K |
| 72050 | <1% | 79 | $4K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 2,757 | $4K |
| L0172 | Cervical, collar, semi-rigid thermoplastic foam, two-piece, prefabricated, off-the-shelf | <1% | 477 | $4K |
| C1729 | Catheter, drainage | <1% | 978 | $4K |
| 80178 | <1% | 1,599 | $4K | |
| 87902 | <1% | 26 | $4K | |
| 82103 | <1% | 665 | $4K | |
| 83521 | <1% | 326 | $4K | |
| 86800 | <1% | 534 | $4K | |
| 86256 | <1% | 581 | $4K | |
| 84480 | <1% | 563 | $4K | |
| 83498 | <1% | 422 | $4K | |
| 98967 | <1% | 330 | $4K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 216 | $4K |
| 87075 | <1% | 2,643 | $4K | |
| 77085 | <1% | 79 | $4K | |
| 93922 | <1% | 196 | $4K | |
| 85379 | <1% | 7,533 | $3K | |
| 86645 | <1% | 527 | $3K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 40 | $3K |
| 82952 | <1% | 1,584 | $3K | |
| 0154A | <1% | 83 | $3K | |
| 97129 | <1% | 317 | $3K | |
| 85014 | <1% | 13,448 | $3K | |
| 92651 | <1% | 50 | $3K | |
| 99406 | <1% | 250 | $3K | |
| 87428 | <1% | 99 | $3K | |
| 99496 | <1% | 51 | $3K | |
| 86039 | <1% | 593 | $3K | |
| 82024 | <1% | 203 | $3K | |
| 84207 | <1% | 268 | $3K | |
| 86381 | <1% | 264 | $3K | |
| 83090 | <1% | 437 | $3K | |
| 93298 | <1% | 207 | $3K | |
| 86141 | <1% | 457 | $3K | |
| 86705 | <1% | 731 | $3K | |
| 83525 | <1% | 484 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 250 | $3K |
| 82150 | <1% | 1,472 | $3K | |
| 85384 | <1% | 1,530 | $3K | |
| 73100 | <1% | 884 | $3K | |
| 80159 | <1% | 278 | $3K | |
| 92552 | <1% | 144 | $3K | |
| 84132 | <1% | 9,610 | $3K | |
| 82652 | <1% | 296 | $3K | |
| 86308 | <1% | 2,239 | $3K | |
| 88271 | <1% | 121 | $3K | |
| 86036 | <1% | 522 | $3K | |
| 86355 | <1% | 209 | $3K | |
| 93312 | <1% | 14 | $3K | |
| 86334 | <1% | 256 | $3K | |
| 88360 | <1% | 437 | $3K | |
| 70546 | <1% | 40 | $3K | |
| 97014 | <1% | 354 | $3K | |
| 62270 | <1% | 15 | $2K | |
| 73720 | <1% | 13 | $2K | |
| 85576 | <1% | 90 | $2K | |
| 83014 | <1% | 618 | $2K | |
| 77290 | <1% | 15 | $2K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 25 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 13,655 | $2K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 1,088 | $2K |
| 82805 | <1% | 773 | $2K | |
| 86812 | <1% | 172 | $2K | |
| 84134 | <1% | 371 | $2K | |
| 72126 | <1% | 138 | $2K | |
| 90716 | <1% | 2,121 | $2K | |
| 87252 | <1% | 219 | $2K | |
| 86231 | <1% | 366 | $2K | |
| 94726 | <1% | 330 | $2K | |
| 87254 | <1% | 236 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,381 | $2K |
| 90837 | Psychotherapy session, about an hour | <1% | 23 | $2K |
| 72081 | <1% | 367 | $2K | |
| 73560 | <1% | 413 | $2K | |
| 71100 | <1% | 184 | $2K | |
| 88237 | <1% | 128 | $2K | |
| 84145 | <1% | 2,208 | $2K | |
| 85613 | <1% | 449 | $2K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 1,203 | $2K |
| 82310 | <1% | 1,023 | $2K | |
| 88264 | <1% | 113 | $2K | |
| 99188 | <1% | 2,509 | $2K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 69,151 | $2K |
| 36410 | <1% | 1,104 | $2K | |
| 76377 | <1% | 5,961 | $2K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 2,396 | $2K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 1,714 | $2K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 4,483 | $2K |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 3,615 | $2K |
| 96381 | <1% | 121 | $2K | |
| 90620 | <1% | 70 | $2K | |
| 81241 | <1% | 53 | $2K | |
| 86317 | <1% | 247 | $2K | |
| 80165 | <1% | 356 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 17 | $2K |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | <1% | 254 | $2K |
| 90648 | <1% | 6,032 | $2K | |
| 82542 | <1% | 888 | $2K | |
| 77073 | <1% | 315 | $2K | |
| 96132 | <1% | 157 | $2K | |
| A9270 | Non-covered item or service | <1% | 11,027 | $2K |
| 86644 | <1% | 351 | $1K | |
| 86357 | <1% | 93 | $1K | |
| Q3014 | Telehealth originating site facility fee | <1% | 70 | $1K |
| 80177 | <1% | 813 | $1K | |
| 82465 | <1% | 525 | $1K | |
| 90688 | <1% | 134 | $1K | |
| 80175 | <1% | 237 | $1K | |
| 73070 | <1% | 361 | $1K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 30 | $1K |
| 83605 | <1% | 16,631 | $1K | |
| 88300 | <1% | 3,737 | $1K | |
| 86708 | <1% | 205 | $1K | |
| 87116 | <1% | 1,857 | $1K | |
| 90662 | <1% | 59 | $1K | |
| 20553 | <1% | 15 | $1K | |
| 70250 | <1% | 235 | $981.81 | |
| 29075 | <1% | 12 | $979.79 | |
| 72190 | <1% | 127 | $957.42 | |
| 0053A | <1% | 28 | $938.25 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 53 | $927.68 |
| 64999 | <1% | 16 | $926.16 | |
| 90694 | <1% | 80 | $919.02 | |
| 73600 | <1% | 168 | $904.52 | |
| 88344 | <1% | 12 | $904.25 | |
| 86850 | <1% | 22,973 | $884.47 | |
| 72220 | <1% | 67 | $868.75 | |
| 84075 | <1% | 398 | $866.73 | |
| 73620 | <1% | 192 | $850.48 | |
| 92602 | <1% | 12 | $832.68 | |
| 83520 | <1% | 2,039 | $812.41 | |
| 82378 | <1% | 126 | $806.60 | |
| 86592 | <1% | 347 | $805.34 | |
| 98966 | <1% | 119 | $789.51 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 285 | $787.44 |
| J1611 | Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg | <1% | 24 | $783.06 |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 15 | $780.07 |
| 70480 | <1% | 13 | $778.08 | |
| 82010 | <1% | 3,280 | $775.65 | |
| 88313 | <1% | 816 | $760.61 | |
| 87210 | <1% | 4,220 | $734.75 | |
| 0074A | <1% | 32 | $730.26 | |
| 89230 | <1% | 24 | $681.91 | |
| 84520 | <1% | 368 | $665.34 | |
| 97167 | <1% | 14 | $645.02 | |
| 0073A | <1% | 17 | $638.01 | |
| 92524 | <1% | 12 | $633.40 | |
| 84244 | <1% | 66 | $632.31 | |
| 92567 | <1% | 3,204 | $625.73 | |
| 86258 | <1% | 50 | $620.01 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,041 | $612.50 |
| 87015 | <1% | 1,842 | $610.99 | |
| 69210 | <1% | 107 | $604.38 | |
| 87521 | Neg quan hep c or qual rna | <1% | 42 | $603.04 |
| 77075 | <1% | 13 | $599.19 | |
| 87209 | <1% | 68 | $594.19 | |
| 96138 | <1% | 158 | $587.19 | |
| 83930 | <1% | 973 | $578.68 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 4,492 | $559.18 |
| 82139 | <1% | 77 | $553.44 | |
| 87106 | <1% | 133 | $552.95 | |
| 85045 | <1% | 749 | $533.47 | |
| 0064A | <1% | 14 | $529.90 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 92,604 | $521.16 |
| 86709 | <1% | 188 | $518.84 | |
| 82164 | <1% | 88 | $512.62 | |
| 84154 | <1% | 55 | $510.41 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12 | $483.00 |
| 0003A | <1% | 13 | $478.00 | |
| 62322 | <1% | 12 | $475.52 | |
| 81003 | <1% | 3,306 | $469.73 | |
| 82365 | <1% | 431 | $458.52 | |
| 76506 | <1% | 12 | $458.40 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 25 | $456.05 |
| S9442 | Birthing classes, non-physician provider, per session | <1% | 14 | $453.74 |
| 84295 | <1% | 8,410 | $435.48 | |
| 90744 | <1% | 1,781 | $433.92 | |
| 85660 | <1% | 225 | $430.24 | |
| 86698 | <1% | 126 | $416.36 | |
| 96402 | <1% | 14 | $403.81 | |
| 69209 | <1% | 202 | $392.61 | |
| 12011 | <1% | 2,651 | $368.24 | |
| 86922 | <1% | 71 | $359.54 | |
| 94618 | <1% | 126 | $355.63 | |
| 84080 | <1% | 47 | $354.65 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | <1% | 25 | $350.24 |
| 89051 | <1% | 3,515 | $348.85 | |
| 82379 | <1% | 64 | $342.21 | |
| 92551 | <1% | 44 | $339.78 | |
| 86060 | <1% | 106 | $337.35 | |
| 30901 | <1% | 12 | $333.05 | |
| 96136 | <1% | 111 | $332.90 | |
| 83835 | <1% | 44 | $332.89 | |
| 87101 | <1% | 78 | $321.44 | |
| 87177 | <1% | 68 | $294.35 | |
| 88312 | <1% | 1,031 | $292.57 | |
| 83051 | <1% | 144 | $286.65 | |
| 82077 | <1% | 4,711 | $285.45 | |
| 46600 | <1% | 72 | $264.53 | |
| 86880 | <1% | 360 | $257.66 | |
| 76775 | <1% | 110 | $254.79 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 69 | $247.95 |
| 80305 | <1% | 1,015 | $236.22 | |
| 83721 | <1% | 42 | $228.54 | |
| 86765 | <1% | 76 | $224.28 | |
| 87385 | <1% | 72 | $220.06 | |
| 93290 | <1% | 695 | $211.67 | |
| 82955 | <1% | 58 | $209.90 | |
| 0296T | <1% | 660 | $208.01 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 53,391 | $205.52 |
| 90653 | <1% | 17 | $199.39 | |
| 82731 | <1% | 67 | $197.02 | |
| 87449 | <1% | 62 | $184.21 | |
| 82803 | <1% | 8,667 | $170.67 | |
| 76942 | <1% | 3,263 | $162.37 | |
| 92582 | <1% | 12 | $162.30 | |
| 36591 | <1% | 14 | $161.97 | |
| 84432 | <1% | 27 | $161.22 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 66,798 | $153.28 |
| 93325 | <1% | 11,914 | $152.04 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 3,564 | $149.35 |
| 86682 | <1% | 28 | $144.59 | |
| 85303 | <1% | 25 | $144.06 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 37 | $142.50 |
| 84300 | <1% | 118 | $138.12 | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 2,677 | $137.74 |
| 96040 | <1% | 654 | $134.92 | |
| 88302 | <1% | 109 | $131.79 | |
| 86337 | <1% | 12 | $131.45 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 51,271 | $129.69 |
| 82085 | <1% | 40 | $120.11 | |
| 88275 | <1% | 13 | $119.01 | |
| 88341 | <1% | 2,323 | $115.73 | |
| 87305 | <1% | 66 | $112.36 | |
| 84112 | <1% | 140 | $111.16 | |
| 83935 | <1% | 46 | $108.80 | |
| 85049 | <1% | 66 | $107.77 | |
| 83010 | <1% | 149 | $105.51 | |
| 12001 | <1% | 2,739 | $104.34 | |
| 70360 | <1% | 42 | $102.17 | |
| 88142 | <1% | 13 | $101.84 | |
| 86707 | <1% | 16 | $101.70 | |
| 12002 | <1% | 1,266 | $100.76 | |
| 87807 | <1% | 15 | $99.58 | |
| 76380 | <1% | 31 | $95.84 | |
| 83695 | <1% | 16 | $93.96 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 72,368 | $91.85 |
| 85306 | <1% | 13 | $91.20 | |
| 86593 | <1% | 38 | $90.82 | |
| 86985 | <1% | 58 | $88.75 | |
| 77001 | <1% | 318 | $86.71 | |
| 82272 | <1% | 573 | $84.12 | |
| 87350 | <1% | 13 | $80.21 | |
| 86735 | <1% | 15 | $80.08 | |
| 49424 | <1% | 182 | $75.16 | |
| 80143 | <1% | 3,526 | $74.48 | |
| L3808 | Wrist hand finger orthosis, rigid without joints, may include soft interface material; straps, custom fabricated, includes fitting and adjustment | <1% | 83 | $68.41 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 90,447 | $67.80 |
| 93321 | <1% | 1,727 | $61.21 | |
| 76937 | <1% | 1,663 | $54.78 | |
| 99152 | <1% | 4,202 | $45.14 | |
| 80183 | <1% | 14 | $44.41 | |
| 82157 | <1% | 12 | $41.68 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 7,988 | $41.22 |
| 82044 | <1% | 138 | $40.92 | |
| 81002 | <1% | 216 | $40.33 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 10,024 | $39.60 |
| J2704 | Injection, propofol, 10 mg | <1% | 60,835 | $35.93 |
| 83986 | <1% | 442 | $35.73 | |
| 81000 | <1% | 298 | $33.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 60 | $30.80 |
| 88720 | <1% | 30 | $30.40 | |
| 92650 | <1% | 147 | $29.79 | |
| 82270 | <1% | 13 | $29.28 | |
| 90715 | <1% | 7,748 | $28.97 | |
| 82075 | <1% | 5,502 | $28.62 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 8,894 | $27.41 |
| 87185 | <1% | 33 | $26.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 11,677 | $25.49 |
| 82945 | <1% | 156 | $25.34 | |
| 87181 | <1% | 16 | $23.39 | |
| 82375 | <1% | 66 | $21.63 | |
| 80179 | <1% | 3,272 | $20.60 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 79 | $19.36 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 12,203 | $18.64 |
| 87899 | <1% | 39 | $17.58 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 22,780 | $17.14 |
| 92555 | <1% | 97 | $16.28 | |
| 91303 | <1% | 127 | $16.00 | |
| 93320 | <1% | 9,951 | $14.99 | |
| 82800 | <1% | 1,083 | $12.99 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 32,173 | $10.84 |
| 87071 | <1% | 209 | $10.29 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,887 | $9.81 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 28,420 | $9.08 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,868 | $8.90 |
| 86703 | <1% | 19 | $8.61 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,467 | $8.06 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 3,467 | $7.26 |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 328 | $7.25 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 2,080 | $7.01 |
| 84157 | <1% | 487 | $6.95 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 12,192 | $5.51 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 12 | $2.13 |
| 82962 | <1% | 13 | $1.95 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 7,000 | $1.70 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 4,843 | $1.10 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 69 | $0.84 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 657 | $0.09 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 690 | $0.00 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 0% | 553 | $0.00 |
| 90723 | 0% | 4,820 | $0.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 5,112 | $0.00 |
| 95886 | 0% | 464 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 3,200 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 4,823 | $0.00 |
| 90680 | 0% | 6,146 | $0.00 | |
| 88311 | 0% | 953 | $0.00 | |
| 90696 | 0% | 1,699 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 2,208 | $0.00 |
| 88185 | 0% | 1,683 | $0.00 | |
| 90698 | 0% | 3,063 | $0.00 | |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 0% | 134 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 12,951 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 1,650 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 758 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 10,120 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 776 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 7,150 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 4,966 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 882 | $0.00 |
| 94644 | 0% | 861 | $0.00 | |
| 91301 | 0% | 797 | $0.00 | |
| 90632 | 0% | 280 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,219 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 22,753 | $0.00 |
| J9250 | Methotrexate sodium, 5 mg | 0% | 757 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 341 | $0.00 |
| 91307 | 0% | 1,034 | $0.00 | |
| 86901 | 0% | 1,390 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 2,235 | $0.00 |
| C1886 | Catheter, extravascular tissue ablation, any modality (insertable) | 0% | 106 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 1,912 | $0.00 |
| 96368 | 0% | 134 | $0.00 | |
| A4217 | Sterile water/saline, 500 ml | 0% | 58 | $0.00 |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 572 | $0.00 |
| 87176 | 0% | 417 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 1,677 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 5,053 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 233 | $0.00 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 0% | 108 | $0.00 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 567 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 723 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 51 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 202 | $0.00 |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 0% | 275 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 292 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 2,199 | $0.00 |
| Q0240 | Injection, casirivimab and imdevimab, 600 mg | 0% | 119 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 420 | $0.00 |
| 94660 | 0% | 59 | $0.00 | |
| 95885 | 0% | 97 | $0.00 | |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 67 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 200 | $0.00 |
| 82438 | 0% | 24 | $0.00 | |
| 51600 | 0% | 173 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 1,057 | $0.00 |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | 0% | 84 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 1,389 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 59 | $0.00 |
| 96139 | 0% | 135 | $0.00 | |
| 76998 | 0% | 136 | $0.00 | |
| 85008 | 0% | 70 | $0.00 | |
| 81511 | 0% | 58 | $0.00 | |
| 80320 | 0% | 15 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 321 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 1,298 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 13 | $0.00 |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 0% | 12 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 107 | $0.00 |
| 84270 | 0% | 53 | $0.00 | |
| 91306 | 0% | 12 | $0.00 | |
| 82657 | 0% | 16 | $0.00 | |
| C1778 | Lead, neurostimulator (implantable) | 0% | 12 | $0.00 |
| J2805 | Injection, sincalide, 5 micrograms | 0% | 25 | $0.00 |
| 30300 | 0% | 13 | $0.00 | |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | 0% | 13 | $0.00 |
| G0288 | Reconstruction, computed tomographic angiography of aorta for surgical planning for vascular surgery | 0% | 15 | $0.00 |
| 83883 | 0% | 14 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 831 | $0.00 |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 772 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 2,323 | $0.00 |
| 90700 | 0% | 1,503 | $0.00 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 1,230 | $0.00 |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | 0% | 575 | $0.00 |
| 90461 | 0% | 13,271 | $0.00 | |
| 29125 | 0% | 1,027 | $0.00 | |
| 90710 | 0% | 1,753 | $0.00 | |
| 85347 | 0% | 1,312 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 5,210 | $0.00 |
| 82397 | 0% | 406 | $0.00 | |
| 82610 | 0% | 1,230 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 4,169 | $0.00 |
| 75565 | 0% | 543 | $0.00 | |
| 90380 | 0% | 100 | $0.00 | |
| 0042T | 0% | 330 | $0.00 | |
| J9370 | Vincristine sulfate, 1 mg | 0% | 2,255 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 1,947 | $0.00 |
| 95874 | 0% | 12 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 131 | $0.00 |
| 93226 | 0% | 1,496 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 367 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 310 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 1,042 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 192 | $0.00 |
| 77002 | 0% | 1,084 | $0.00 | |
| 76376 | 0% | 79 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 4,853 | $0.00 |
| 90707 | 0% | 2,117 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 704 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 2,841 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 224 | $0.00 |
| 90633 | 0% | 4,379 | $0.00 | |
| C8937 | Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure) | 0% | 176 | $0.00 |
| 77012 | 0% | 493 | $0.00 | |
| 91321 | 0% | 376 | $0.00 | |
| 0722T | 0% | 45 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 157 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 466 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 311 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 418 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 518 | $0.00 |
| 90685 | 0% | 170 | $0.00 | |
| 94729 | 0% | 634 | $0.00 | |
| 93356 | 0% | 1,317 | $0.00 | |
| 23350 | 0% | 163 | $0.00 | |
| 90714 | 0% | 108 | $0.00 | |
| 27093 | 0% | 15 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 456 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 313 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 510 | $0.00 |
| 91300 | 0% | 15,078 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 737 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 102 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 80 | $0.00 |
| 82523 | 0% | 31 | $0.00 | |
| J7070 | Infusion, d5w, 1000 cc | 0% | 70 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 44 | $0.00 |
| 91312 | 0% | 630 | $0.00 | |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 147 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 43 | $0.00 |
| L3913 | Hand finger orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment | 0% | 68 | $0.00 |
| 51701 | 0% | 88 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 31 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 114 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 315 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 105 | $0.00 |
| 64643 | 0% | 79 | $0.00 | |
| 0159T | 0% | 30 | $0.00 | |
| 96133 | 0% | 116 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 19 | $0.00 |
| C1874 | Stent, coated/covered, with delivery system | 0% | 14 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 153 | $0.00 |
| J9260 | Injection, methotrexate sodium, 50 mg | 0% | 58 | $0.00 |
| 15853 | 0% | 28 | $0.00 | |
| 96137 | 0% | 25 | $0.00 | |
| J3250 | Injection, trimethobenzamide hcl, up to 200 mg | 0% | 51 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 57 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 28 | $0.00 |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 12 | $0.00 |
| 41800 | 0% | 38 | $0.00 | |
| 99215 | Doctor's office visit, returning patient (complex) | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOX, MATTHEW (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.